Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference
13 February 2020
Read the announcement that REPROCELL Europe’s Prof Stefan Przyborski will giving the keynote address on 3D cell culture at the SMi Annual Conference London
Patients with IBD absorb drugs differently from healthy individuals
16 January 2020
Read about how a recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals.
REPROCELL can now predict oral bioavailability in fresh IBD tissue
14 January 2020
REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal resections from IBD donors.
Early understanding of pharmacology and genomics can improve precision medicine strategies
23 December 2019
REPROCELL announce the successful publication of a novel study in pharmacology and genomics to improve strategies for precision medicine.
Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services
13 November 2019
Lantern Pharma, a biotech leveraging A.I. and machine learning, has selected REPROCELL Inc. to provide drug screening and drug sensitivity services.
Appointment of New Distributor in Thailand
04 November 2019
Read about the REPROCELL groups distributorship agreement with A.N.H. Scientific Marketing Co. Ltd. to distribute REPROCELL’s products and services in Thailand
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
25 September 2019
This new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons.
PRESS RELEASE: ABLE Biott Bioreactors now available in Europe
22 August 2019
REPROCELL announce the launch of ABLE Biott Bioreactors in Europe. The lab-scale system will allow researchers to culture stem cells in suspension.
REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification
08 April 2019
Find out about REPROCELL USA's recently achieved ISO9001:2015 accreditation. demonstrating its ability to consistently meet customer requirements
REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories
28 February 2019
REPROCELL Inc. and Fox Chase, Ltd., have formed a joint venture to begin operations of multi-site biosample repository facilities globally.
ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production
10 October 2018
Learn more about the partnership between REPROCELL and ROSLINCT aiming to improve efficiency of induced pluripotent stem cell production
Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan
01 August 2018
Read the Japan Pharmaceuticals and Medical Device Agency's announcement that REPROCELL has acheived PMDA Approval of CTN for Phase II Trial of Stemchymal
Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services
21 June 2018
Read more about how REPROCELL’s BioServe and Biopta tissue procurement networks have combined to create a new service isolating human primary cells.
REPROCELL’s footprint extends to serve life sciences in India
13 June 2018
Learn more about REPROCELL India's expansion into the life sciences industry through the integration of Oligonucleotide Services and Next Generation Sequencing
Acquisition of BioServe Biotechnologies India Pvt. Ltd.
26 April 2018
REPROCELL announces that it has acquired Bioserve biotechnologies, further expanding REPROCELL's portfolio of service offerings
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
06 April 2018
Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017
REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery
13 April 2017
REPROCELL and Fox Chase Cancer Center have announced a strategic alliance aimed at accelerating oncology discovery and translational studies, read more